www.fdanews.com/articles/150796-sanofi-regeneron-commence-patient-recruitment-in-phase-iii-cvot
Sanofi, Regeneron Commence Patient Recruitment in Phase III CVOT
November 6, 2012
Sanofi and Regeneron Pharmaceuticals have commenced patient recruitment in a Phase III cardiovascular outcomes trial (CVOT) to test SAR236553/REGN727, designed to lessen low-density lipoprotein cholesterol levels.
Pharmaceutical Business Review
Pharmaceutical Business Review